Atypical metatarsal fracture in a patient on long term bisphosphonate therapy

Indian Journal of Orthopaedics

Volumn 46, Issue 5, 2012, Pages 589-592

  Pradhan, Pavan ^a   Saxena, Vikas ^a   Yadav, Ashok ^a   Mehrotra, Vineet ^a  

^a BRD MEDICAL COLLEGE   (India)

Author keywords

Atypical fracture; bisphosphonate; metatarsal

Indexed keywords

EID: 84867355847     PISSN: 00195413     EISSN: 19983727     Source Type: Journal    
DOI: 10.4103/0019-5413.101048     Document Type: Article

References (32)

1. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: Pharmacology, mechanisms of action and clinical uses. Osteoporosis Int. 1999;9(suppl 2):S66-80.
2. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80-100. (Pubitemid 29122075)
3. Roux C, Dougados M. Bisphosphonate in the prevention and treatment of glucocorticoid-induced osteoporosis. Clin Exp Rheumatol 2000;18 (suppl. 21):S49-52.
4. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of Risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282:1344-52. (Pubitemid 29483192)
5. American college of rheumatology Adhoc committee on glucocorticoid - induced osteoporosis: Recommendation for the prevention and treatment of glucocorticoid - induced osteoporosis. 2001 Update. Available from: http//www.rheumatology.org [Last cited on 2011 Sep 07].
6. Imai K, Yamamoto S, Anamizu Y, Horiuchi T. Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab. 2007; 25: 3 33-6. (Pubitemid 47283272)
7. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a longterm complication of alendronate therapy? Injury 2008;39:224-31.
8. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing fracture. Fracture intervention trial Research Group. Lancet 1996;348:1535-41. (Pubitemid 26411651)
9. Chan SS, Rosenberg ZS, Chan K, Capeci C. Subtrochanteric femoral fractures in patients receiving longterm alendronate therapy: Imaging features. AJR Am J Roentgenol 2010;194:1581-6.
10. Krestan C, Hojreh A. Imaging of insufficiency features. Eur J Radiol 2009;71:398-405.
11. Spitz DJ, Newberg AH. Imaging of stress fractures in the athelete. Radiol Clin North Am 2002;40:313-31.
12. Seeman E, Delmas PD. Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol Metab 2001;12:281-3 (Pubitemid 33714219)
13. Drake MT, Clarke BL, Khosala S. Bisphosphonate: Mechanism of action and role in clinical practice. Mayo Clin Proc 2008;83:1032-45.
14. Yeap SS, Hosking DJ. Management of corticosteroid - induced osteoporosis. Rheumatology 2002;41:1088-94.
15. US Food and Drug administration. FDA Drug safety communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm229009. [Last cited on 2010 Oct 13].
16. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but with out vertebral fractures. JAMA December 23/30, 1998;280:2077-82. (Pubitemid 29014065)
17. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing of stopping alendronate after 5 years of treatment: the fracture intervention trial long term extension (FLEX): a randomized trial. JAMA 2006;296:2927-38. (Pubitemid 46021497)
18. Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 2005;87:731-41. (Pubitemid 40489347)
19. Saag KG, Shane E, Boonen S, Marn F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39. (Pubitemid 350106710)
20. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006;147:5592-9. (Pubitemid 44833476)
21. Forteo (teriparatide, Eli Lilly and Company, Indianapolis, IN). Full prescribing information, 2002.
22. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301. (Pubitemid 40463979)
23. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br 2007;89:349-53. (Pubitemid 46563912)
24. Agarwal S, Agarwal S, Gupta P, Agarwal PK, Agarwal G, Bansal A. Risk of atypical fracture with long term use of alendronate (Bisphosphonate): A systemic review of literature. Acta Orthop Belg 2010;76:567-71.
25. Cheung RK, Leung KK, Lee KC, Chow TC. Sequential non traumatic femoral shaft fractures in a patient on long term alendronate. Hong Kong Med J 2007;13:485-9. (Pubitemid 351206686)
26. Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001;69:281-6. (Pubitemid 33140938)
27. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001;28:524-31. (Pubitemid 32416465)
28. Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation? Bone 2000;21:13-20. (Pubitemid 30365072)
29. Boivin G, Meunier PJ. Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res 2002;43:535-7. (Pubitemid 34777975)
30. Akkus O, Polyakova-Akkus A, Adar F, Schaffler MB. Aging and microstructural compartments in human compact bone. J Bone Miner Res 2003;18:1012-9. (Pubitemid 37294937)
31. Ciarella TE, Fyhrie DP, Parfitt AM. Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone 2003;32:311-5. (Pubitemid 36349535)
32. Currey JD. Effects of differences in mineralization on the mechanical properties of bone. Philos Trans R Soc Lond B Biol Sci 1984;304:509-18.